Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPrognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer
Journal of Thoracic Oncology, 06/29/09
Custodio AB et al. - Patients with early stage NSCLC are at substantial risk for recurrence even after potentially curative surgical resection, and adjuvant chemotherapy. The current staging system is inadequate for predicting the outcome of treatment and the prognosis in an individual patient. Molecular markers may provide additional information about the likelihood of relapse beyond that obtained from pathologic staging. They may also have value in determining which patients will benefit from adjuvant platinum-based chemotherapy. This review focuses on:
- Approaches and specific markers under study
- Gene expression profiles
- DNA repair pathways
- Class III β-tubulin expression
- Abnormalities in the k-ras oncogene and p53 tumor suppressor gene, and
- DNA methylation markers
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Breast cancer in the elderly: a histological assessment
Histopathology, 10/15/09
Serum calcium levels are elevated among women with untreated postmenopausal breast cancer
Cancer Causes and Control, 11/03/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Sponsor
Article Search
Sponsor
Sponsor